Ananda Walaliyadda, MD
Rheumatology · Pocatello, IDNPI 1497747703
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $973 of the $1,181 with a category attached, or 82.3%. 15 manufacturers reported payments, led by Amgen at 42.0% of the total. That places this record below the midpoint for rheumatology clinicians in ID, where the typical reported total is $1,851.
Across 61 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$496
- Johnson & Johnson$307
- GSK$78
- AstraZeneca$69
- UCB, Inc.$35
- Novartis$29
- plus $167 from 9 others
What the payments were for
- Food & beverage$97382%
- Education$20918%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 28 | $496 |
| Johnson & Johnson | 11 | $307 |
| GSK | 5 | $78 |
| AstraZeneca | 4 | $69 |
| UCB, Inc. | 1 | $35 |
| Novartis | 2 | $29 |
| Bristol Myers Squibb | 1 | $25 |
| Boston Scientific | 1 | $25 |
| Organon | 2 | $22 |
| Genentech USA, Inc. | 1 | $21 |
| Sandoz | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Pfizer | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
How this compares
$1,181 in reported general payments places this provider in the 45th percentile of 28 rheumatology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 46 | $372,426 |
| RinvoqUpadacitinib | 31 | $237,832 |
| Xeljanz XrTofacitinib Citrate | 15 | $82,965 |
| KevzaraSarilumab | 14 | $59,619 |
| Hydroxychloroquine Sulfate | 175 | $7,044 |
| Celecoxib | 60 | $5,706 |
| Leflunomide | 82 | $5,152 |
| MethotrexateMethotrexate Sodium | 195 | $4,257 |
| Colchicine | 20 | $3,015 |
| Leucovorin Calcium | 56 | $2,549 |
| Prednisone | 255 | $1,460 |
| Sulfasalazine | 42 | $1,005 |
| Allopurinol | 92 | $894 |
| Gabapentin | 23 | $281 |
| Trazodone Hcl | 21 | $273 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Pocatello
- Dustin DinningCoeur D Alene$311K
- William KnibbeBoise$164K
- Craig ScovilleIdaho Falls$26K
- Christopher GibsonAshton$18K
- James LovelessBoise$12K
- Peggy Ann RuppBoise$11K
- Craig WiesenhutterCoeur D Alene$7K
- Sean McMillanTwin Falls$4K
- Francis NardellaMeridian$3K
- Linda SakaiCoeur D Alene$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.